Table 4.
Prognostic Factors for DFS/PFS and OS for the Patients in PD-L1-Positive Group
| Characteristics | DFS/PFS | OS | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate Analysis | Multivariate Analysis | Univariate Analysis | Multivariate Analysis | |||||
| HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Age (years) | 1.043 (0.984–1.106) | 0.157 | 1.052 (0.978–1.132) | 0.174 | ||||
| Gender (Male/Female) |
1.653 (0.596–4.583) | 0.334 | 1.969 (0.553–7.008) | 0.295 | ||||
| TNM stage (I–II/III–IV) |
6.150 (1.705–22.179) | 0.006 | 7.480 (1.919–29.156) | 0.004 | 4.451 (0.960–21.487) | 0.056 | ||
| Tumor size (mm) | 1.025 (1.000–1.050) | 0.046 | 1.026 (0.995–1.058) | 0.009 | ||||
| Tumor differentiation Well/Moderate or poor |
1.990 (0.632–6.262) | 0.239 | 2.739 (0.581–12.919) | 0.203 | ||||
| CEA (ng/mL) | 1.008 (1.000–1.016) | 0.062 | 1.010 (1.001–1.019) | 0.027 | 1.010 (1.000–1.020) | 0.045 | ||
| Ki67 | 1.022 (0.995–1.049) | 0.110 | 1.033 (1.000–1.066) | 0.049 | ||||
| PD-1 | 0.873 (0.712–1.070) | 0.191 | 0.883 (0.689–1.132) | 0.327 | ||||
| GLUT1 | 1.244 (0.949–1.632) | 0.114 | 1.332 (0.927–1.916) | 0.121 | ||||
| HK-II | 1.268 (0.985–1.631) | 0.065 | 1.303 (0.941–1.805) | 0.111 | ||||
| SUVmax | 1.104 (1.000–1.219) | 0.050 | 1.156 (1.021–1.309) | 0.022 | 1.146 (1.020–1.289) | 0.022 | ||
| MTV (cm3) | 1.027 (0.998–1.058) | 0.068 | 1.032 (1.004–1.062) | 0.027 | ||||
| TLG (cm3) | 1.003 (1.000–1.005) | 0.021 | 1.003 (1.001–1.006) | 0.007 | 1.003 (1.001–1.006) | 0.012 | ||
Abbreviations: DFS, disease-free survival; PFS, progression-free survival; OS, overall survival; PD-L1, programmed death ligand-1; CEA, carcino-embryonic antigen; PD-1, programmed death-1; GLUT-1, glucose transporter 1; HK-II, hexokinase II; SUVmax, maximum standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis.